ACME Laboratories (DHA:ACMELAB) NonCurrent Deferred Liabilities: BDT0 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

DHA:ACMELAB ACME Laboratories Ltd DHA:ACMELAB
85 GF Score
Price BDT82.80
GF Value BDT126.24
Valuation Possible Value Trap
! 8 Warning Signs
View Full Analysis

What is ACME Laboratories NonCurrent Deferred Liabilities?

ACME Laboratories DHA:ACMELAB -0.84% 85 NonCurrent Deferred Liabilities is BDT0 Mil as of Mar. 2026. GuruFocus rates DHA:ACMELAB with a GF Score™ of 85/100 and a GF Value™ of BDT126.24 (Possible Value Trap). The stock has 8 warning signs investors should review.

Non-Current Deferred Liabilities represents the non-current portion of obligations, which is a liability that usually would have been paid but is now pas due.

ACME Laboratories's non-current deferred liabilities for the quarter that ended in Mar. 2026 was BDT0 Mil.

ACME Laboratories NonCurrent Deferred Liabilities Related Terms

ACME Laboratories NonCurrent Deferred Liabilities Historical Data

* Premium members only.

The historical data trend for ACME Laboratories's NonCurrent Deferred Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

ACME Laboratories NonCurrent Deferred Liabilities Chart

ACME Laboratories Annual Data
Trend Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24
NonCurrent Deferred Liabilities
Get a 7-Day Free Trial Premium Member Only 0.00 0.00 0.00 0.00 0.00

ACME Laboratories Quarterly Data
Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Sep25 Dec25 Mar26
NonCurrent Deferred Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
DHA:ACMELAB
85GF Score
ACME Laboratories Ltd DHA:ACMELAB
NonCurrent Deferred Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a NonCurrent Deferred Liabilities of BDT0 Mil mean?
ACME Laboratories (DHA:ACMELAB) has a NonCurrent Deferred Liabilities of BDT0 Mil as of Mar. 2026. Non-current deferred liabilities represent the company obligations not paid yet not due within the current period. View historical data on ACME Laboratories and its competitors.
Is ACME Laboratories' NonCurrent Deferred Liabilities too high?
ACME Laboratories' current NonCurrent Deferred Liabilities is BDT0 Mil. Overall, ACME Laboratories has a GF Score™ of 85/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does ACME Laboratories' NonCurrent Deferred Liabilities compare to ZTS and UTHR?
ACME Laboratories' NonCurrent Deferred Liabilities of BDT0 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good NonCurrent Deferred Liabilities for a Drug Manufacturers company?
A good NonCurrent Deferred Liabilities depends on the Drug Manufacturers industry context. However, NonCurrent Deferred Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high NonCurrent Deferred Liabilities mean?
A high NonCurrent Deferred Liabilities can signal that a stock is expensive relative to its fundamentals. Non-current deferred liabilities represent the company obligations not paid yet not due within the current period. View historical data on ACME Laboratories and its competitors. ACME Laboratories's current NonCurrent Deferred Liabilities is BDT0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ACME Laboratories stock overvalued right now?
Based on GuruFocus' analysis, ACME Laboratories (DHA:ACMELAB) is currently considered Possible Value Trap. The stock's GF Value™ is BDT126.24, compared to a current price of BDT82.80 — trading 34.4% below its estimated fair value. The current NonCurrent Deferred Liabilities is BDT0 Mil. ACME Laboratories' overall GF Score™ is 85/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is NonCurrent Deferred Liabilities calculated?
NonCurrent Deferred Liabilities is calculated from a company's financial statements. For ACME Laboratories (DHA:ACMELAB), the current NonCurrent Deferred Liabilities is BDT0 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is ACME Laboratories (DHA:ACMELAB) Overvalued in 2026?

Based on GuruFocus' analysis, ACME Laboratories stock appears to be undervalued. The current stock price of BDT82.80 is trading 34.4% below its estimated GF Value™ of BDT126.24. GuruFocus considers ACME Laboratories to be Possible Value Trap.

Key valuation signals for DHA:ACMELAB:

  • NonCurrent Deferred Liabilities: BDT0 Mil
  • GF Value™: BDT126.24 vs. price of BDT82.80 (34.4% below fair value)
  • GF Score™: 85/100 with 8 warning signs

No single metric tells the full story. See the DHA:ACMELAB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

ACME Laboratories Business Description

Address 1/4, Kallayanpur, Mirpur Road, Court de la ACME, Dhaka, BGD, 1207
ACME Laboratories Ltd is engaged in the manufacturing, marketing, and distribution of generic pharmaceutical products in Bangladesh. The Company is engaged in manufacturing, marketing, and distribution of generic pharmaceuticals formulation products which includes human drugs comprising dosages form like a tablet, capsule, dry syrup, cream, ointment, powder, injection, dry powder inhaler, metered dosage inhaler, suppository, eye and nasal drop, liquid, liquid in hard gelatine, Blow Fill Seal (BFS) products, sachet products; veterinary drugs comprising dosages form like bolus, liquid,injection, water-soluble powder, premix and herbal drugs comprising dosages form like liquid, capsule, tablet, cream. The products of the company are sold in domestic and international markets.
85GF Score

Get the complete analysis for DHA:ACMELAB

NonCurrent Deferred Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

BDT82.80
Price
BDT126.24
GF Value